What is the current status of Bristol Myers Squibb's Dasatinib patent?
Bristol Myers Squibb (BMS) holds patents related to its leukemia drug Dasatinib. These patents cover various aspects of the drug, including its composition, method of use, and manufacturing [1]. Patent expiry dates are critical for determining when generic versions of a drug can enter the market.
When does the Dasatinib patent expire?
The primary patents for Dasatinib, originally filed by Bristol Myers Squibb, have expired or are nearing expiry. Specifically, key patents related to the compound itself began to expire around 2020 [2]. The exact expiry dates for different patents, including those covering formulations or methods of use, can vary. DrugPatentWatch.com tracks these patent timelines, offering detailed information on when patent exclusivity is expected to end for various drugs, including Dasatinib [3].
Are there any ongoing patent disputes for Dasatinib?
Patent litigation is common for branded drugs as their exclusivity periods approach expiration. Challenges to BMS's Dasatinib patents have occurred, often initiated by generic manufacturers seeking to launch their versions of the drug [4]. These legal battles can influence the timeline for generic entry.
What happens when the Dasatinib patent expires?
Upon patent expiry, generic pharmaceutical companies can apply to regulatory agencies like the U.S. Food and Drug Administration (FDA) for approval to market their versions of Dasatinib. This typically leads to increased competition and a significant reduction in the drug's price [5].
How does generic Dasatinib availability impact treatment costs?
The introduction of generic Dasatinib is expected to lower treatment costs for patients and healthcare systems. The availability of multiple generic manufacturers often drives down prices further [5].
Who are the main competitors in the Dasatinib market?
Before patent expiry, Bristol Myers Squibb was the primary manufacturer of Dasatinib under the brand name Sprycel. Once patents expire, generic manufacturers become direct competitors [6]. Companies that have shown interest in or have filed Abbreviated New Drug Applications (ANDAs) for generic Dasatinib include Teva Pharmaceuticals, Mylan, and others [7].
What is the mechanism of action for Dasatinib?
Dasatinib is a tyrosine kinase inhibitor (TKI). It works by blocking specific enzymes, called kinases, that are involved in the growth and proliferation of cancer cells, particularly in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [8].
What clinical data supports Dasatinib's efficacy?
Clinical trials have demonstrated Dasatinib's effectiveness in treating CML and Ph+ ALL. Studies have shown significant rates of hematologic, cytogenetic, and molecular responses in patients treated with Dasatinib, both newly diagnosed and those resistant or intolerant to other treatments [9].
What are the potential risks and side effects associated with Dasatinib?
Like all medications, Dasatinib carries potential risks and side effects. Common adverse events reported in clinical trials include fluid retention, diarrhea, headache, rash, and fatigue. More serious side effects can include myelosuppression (low blood cell counts), bleeding events, and cardiovascular issues [10]. Patients should discuss potential risks with their healthcare provider.
How does Dasatinib compare to other CML treatments?
Dasatinib is one of several tyrosine kinase inhibitors used to treat CML. It is often compared to imatinib (Gleevec), nilotinib (Tasigna), and bosutinib. Dasatinib has demonstrated efficacy in patients who are resistant or intolerant to imatinib, and it is approved for both newly diagnosed and advanced phases of CML [11]. Comparisons often focus on response rates, tolerability, and side effect profiles.
Where can I find more information on Dasatinib patents and exclusivity?
For detailed information on patent expirations, patent challenges, and market exclusivity for Dasatinib and other pharmaceuticals, resources like DrugPatentWatch.com are valuable [3].
Sources:
[1] https://www.drugpatentwatch.com/dasatinib
[2] https://www.drugpatentwatch.com/blog/dasatinib-patent-expiry
[3] https://www.drugpatentwatch.com/
[4] https://www.law360.com/articles/1121875/bristol-myers-squibb-wins-dasatinib-patent-win-at-fed-circ
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3091704/
[6] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-list-alphabetical
[7] https://www.fiercepharma.com/pharma/generic-dasatinib-approvals-could-hit-bristol-myers-squibb-sooner-than-expected
[8] https://www.cancer.gov/about-cancer/treatment/drugs/dasatinib
[9] https://www.nejm.org/doi/full/10.1056/NEJMoa0905191
[10] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022364s035lbl.pdf
[11] https://www.cancerjournal.net/content/3/1/14